+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06680050

Phase 2 Study of Radiotherapy Followed by Durvalumab and Ceralasertib for Stage III Non-Small Cell Lung Cancer with Thoracic Relapses and Limited Metastases After PACIFIC Treatment

Led by Mario Negri Institute for Pharmacological Research · Updated on 2025-12-18

21

Participants Needed

9

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of thoracic re-irradiation with or without stereotactic body radiotherapy SBRT followed by treatment with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer NSCLC who have thoracic relapses, with or without limited metastatic disease. This phase 2 study focuses on patients who previously received PACIFIC or similar chemo-radiotherapy regimens followed by durvalumab maintenance. The goal is to explore new treatment approaches for patients experiencing disease recurrence after initial therapy. The study treatment begins with radiotherapy targeting local tumor recurrences and regional lymph node metastases with doses ranging from 36 to 50 Gy in daily fractions. Two weeks after completing radiotherapy, participants will start systemic therapy with durvalumab administered by intravenous infusion every four weeks and oral ceralasertib given twice daily for one week in each 28-day cycle. Treatment continues until disease progression, unacceptable side effects, or withdrawal from the study. Participants will undergo regular assessments including imaging scans CT, PET, brain MRI, tumor measurements, and monitoring for side effects. Researchers will evaluate safety by tracking severe treatment-related adverse events over six months and measure progression-free survival at 12 months as the primary outcome. Secondary outcomes include response rates and overall survival at 6 and 12 months. The study requires participants to comply with scheduled visits and follow-up procedures throughout the treatment period.

CONDITIONS

Brief Title

Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

Research Team

I

Irene De Simone, Project manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here